Compare DexCom, Inc. (DXCM) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Sony Group Corp — how do they compare? DexCom, Inc. trades at $77.75 (market cap $28.06B), while Sony Group Corp trades at $21.21 (market cap $123.02B). The key difference: Sony Group Corp is far larger — about 4.4× DexCom, Inc.'s market cap, and Sony Group Corp pays a 0.76% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SONY | |
|---|---|---|
Market Cap | $28.06B | $123.02B |
Sector | Health | Technology |
52-Week High | $89.53 | $30.26 |
52-Week Low | $54.84 | $19.32 |
Enterprise Value | $27.03B | $119.51B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Sony trades at $20.80, up 0.58% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong operating cash flow of $2.32 trillion in 2025, but faces a projected net loss in 2026. Analyst consensus is bullish with 68.75% buy ratings, while recent news highlights Sony's strategic shift to digital-only PlayStation games by 2028.
The outlook is mixed: strong cash flow and analyst support provide upside potential, but 2026's projected loss and bearish technicals pose near-term risks. Investors should weigh the digital transition's long-term benefits against execution challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
